Document is current
Any future updates will be listed below
-
Authors
Roche, Veronique
Sandoval, Victor
Wolford, Claire
Senders, Zachary
Kim, Julian Anthony
Ribeiro, Susan Pereira
Huang, Alex Yicheng
Sekaly, Rafick-Pierre
Lyons, Joshua
Zhang, Mei https://orcid.org/0000-0001-7705-1090
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01829373 at ClinicalTrials.govnct00682032 at ClinicalTrials.govDocuments that mention this clinical trial
Carbohydrate ligand engagement with CD11b enhances differentiation of tumor-associated myeloid cells for immunotherapy of solid cancers
https://doi.org/10.1136/jitc-2022-006205
nct00289003 at ClinicalTrials.govDocuments that mention this clinical trial
Carbohydrate ligand engagement with CD11b enhances differentiation of tumor-associated myeloid cells for immunotherapy of solid cancers
https://doi.org/10.1136/jitc-2022-006205
nct00492167 at ClinicalTrials.govDocuments that mention this clinical trial
Carbohydrate ligand engagement with CD11b enhances differentiation of tumor-associated myeloid cells for immunotherapy of solid cancers
https://doi.org/10.1136/jitc-2022-006205
nct00089258 at ClinicalTrials.govDocuments that mention this clinical trial
Carbohydrate ligand engagement with CD11b enhances differentiation of tumor-associated myeloid cells for immunotherapy of solid cancers
https://doi.org/10.1136/jitc-2022-006205
nct02981303 at ClinicalTrials.govDocuments that mention this clinical trial
Carbohydrate ligand engagement with CD11b enhances differentiation of tumor-associated myeloid cells for immunotherapy of solid cancers
https://doi.org/10.1136/jitc-2022-006205
Documents that mention this clinical trial
P859 Association of immunopharmacodynamic responses of imprime PGG plus pembrolizumab with clinical benefit in metastatic triple negative breast cancer (TNBC) subjects failing front-line chemotherapy
https://doi.org/10.1136/lba2019.13
Carbohydrate ligand engagement with CD11b enhances differentiation of tumor-associated myeloid cells for immunotherapy of solid cancers
https://doi.org/10.1136/jitc-2022-006205
P862 Clinical benefit potentially evident with immunopharmacodynamic responses in prior-checkpoint failed metastatic melanoma patients treated with imprime PGG and pembrolizumab
https://doi.org/10.1136/lba2019.15
-
Funding
Funding for this research was provided by:
Case GI Specialized Program on Research Excellence (Career Enhancement Grant)
Case Comprehensive Cancer Center (Tumor Immunology Science & Initiative Pancreatic)
Department of Defense (DoD) Peer-Review Cancer Research program (E01W81XWH2110804)
- License Information
